Cagrilintide (AM833) Cagrilintide is a long-acting amylin analog designed for once-weekly (OW) SC administration (based on the structure of natural amylin), developed by Novo Nordisk [112]
Never reuse needles between injections
the goal of this study was to develop an AnglV-derived molecule that retained the pro-cognitive/anti-dementia activity of AnglV and Nle'-AnglV but possessed improved pharmacokinetic properties, thus allowing it to penetrate the BBB in sufficient quantities to reach therapeutic levels in the brain
Compound Review does not sell or supply this or any compound
2 Importantly, amylin does not blunt the counter-regulatory glucagon response to hypoglycemia, so this suppression is selective for the postprandial, not the fasting or emergency, context
But given the lack of clinical evidence and the fact that BPC-157 peptides are unregulated, we suggest instead that you bring your symptoms, timeline, and goals to a trusted clinician, like one at Midi